- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about HIMS
Recent news which mentions HIMS
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
October 14, 2024
From Benzinga
Where Does Hims & Hers Stock Go From Here?
October 12, 2024
From Motley Fool
2 Incredibly Cheap Growth Stocks to Buy Right Now
October 12, 2024
From Motley Fool
2 No-Brainer Growth Stocks to Buy With $500 Right Now
October 12, 2024
From Motley Fool
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
October 08, 2024
From Benzinga
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
October 08, 2024
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
From Benzinga
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday
October 07, 2024
From Benzinga
Hims & Hers Health Stock Is Rising Monday: What's Going On?
October 07, 2024
From Benzinga
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
October 04, 2024
From Benzinga
Massive News for Hims & Hers Stock: The Truth About Today's Move
October 04, 2024
From Motley Fool
2 Winning Growth Stocks That Are Screaming Buys Right Now
October 04, 2024
From Motley Fool
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
October 03, 2024
From Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
October 03, 2024
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
October 03, 2024
From Benzinga
From Motley Fool
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
September 19, 2024
From Benzinga
Hims & Hers Acquisition: How Innovation Will Flourish
September 18, 2024
Tickers
HIMS
From Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
September 17, 2024
From Motley Fool
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)
September 13, 2024
Tickers
HIMS
From Benzinga
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
September 11, 2024
Tickers
HIMS
From Motley Fool
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
From Motley Fool
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
September 11, 2024
From Benzinga
From Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
September 05, 2024
From Motley Fool
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
September 05, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.